LT-02, a new optimized delayed release formulation of phosphatidylcholine was developed by Lipid Therapeutics.

In a multicenter multinational clinical phase IIb study the efficacy and safety of LT-02 was explored in patients suffering from ulcerative colitis. The positive outcome of this study provides the basis for pivotal clinical phase III studies necessary for registration and marketing of this novel medication